Fig 4. Kaplan-Meier curves for Progression-Free (PF) Survival Probability on CD44, CD47 and MET expression groups before (a) and after (b) bisphosphonates administration.

Patients with more than the median number of CD44⁺ CD47⁺ MET ⁺ cells (“Triple-positive high” patients) have significantly lower overall survival than “Triple-positive low” patients. The dotted lines show the median overall survival times. Before treatment: 3.86 years for “Triple-positive high” patients versus 4.11 years for “Triple-positive low” patients. After treatment: 4.82 years for “Triple-positive high” patients versus 4.99 years for “Triple-positive low” patients.